主题：【分享】研究消化系统疾病模型新工具-肠类器官

浏览0 回复0 电梯直达

义翘神州

结帖率：

100%

关注：0 |粉丝：0

新手级：新兵

发表于：2024/10/16 10:42:36 楼主管理分享倒序浏览只看楼主回复私聊

前言

现代医学的发展将会获得越来越复杂的数据，时间和空间上高度动态的系统数据将会对诊断、治疗和预测结果提供帮助。类器官有望成为治疗各种胃肠道疾病的高价值系统，用于模拟免疫反应、代谢机制、肿瘤发生与发展、感染性消化道疾病等。截止到2023年7月中旬，全球类器官的临床研究超过170例，其中消化系统疾病的研究有70多例。为了助力类器官的培养和研究，义翘神州可提供自主研发的人源EGF、NOG、RSPO1等重组细胞因子产品。

01肠类器官研究进展

肠类器官（Intestinal organoids）从人类肠道组织或干细胞中分离和培养构建。通过在适当的培养条件下处理这些细胞，可以形成三维的肠道结构。当充分成熟时，人类肠道类器官会重现出芽的隐窝和绒毛结构域，分别含有增殖的ISC和祖细胞，以及分化的肠上皮细胞、杯状细胞和潘氏细胞。

?义翘神州细胞因子产品数据

Human RSPO1 Protein, Cat: 11083-HNAS

高纯度：

高纯度

≥ 95 % as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.

高批间一致性

高批间一致性

Induce activation of ?catenin response in a Topflash Luciferase assay using HEK293T human embryonic kidney cells.

Human Noggin Protein, Cat: 10267-HNAH

高纯度：

高纯度

≥95% as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.

高批间一致性

高批间一致性

Inhibit BMP4-induced alkaline phosphatase production by MC3T3E1 mouse preosteoblast cells.

肠类器官培养相关的细胞因子
货号	靶点	内毒素	纯度及活性
10605-HNAE	EGF	<5 EU/mg	≥95%^☆, Active
GMP-10605-HNAE	EGF	<5 EU/mg	≥95%^☆, Active
GMP-10014-HNAE	FGF2	<10 EU/mg	≥95%, Active
10210-H07E	FGF7	<0.01 EU/μg	≥95%^☆, Active
10267-HNAH	NOG	<10 EU/mg	≥95%^☆, Active
10007-HNAH	CSF3	<10 EU/mg	≥95%^☆, Active
10236-H02H	EPO	<10 EU/mg	≥95%^☆, Active
10573-HNAE	FGF10	<5 EU/mg	≥95%^☆, Active
11858-HNAE	IL3	<5 EU/mg	≥95%^☆, Active
GMP-11858-HNAE	IL3	<5 EU/mg	≥95%^☆, Active
10451-HNAE	KITLG	<10 EU/mg	≥95%^☆, Active
11066-HNAH	VEGFA	<10 EU/mg	≥95%^☆, Active
10424-H08H	VTN	<10 EU/mg	≥95%, Active
10429-HNAH	INHBA	<10 EU/mg	≥95%^☆, Active
GMP-10429-HNAH	INHBA	<10 EU/mg	≥95%^☆, Active
10463-HNAS	HGF	<0.01 EU/μg	≥95%^☆, Active
11083-HNAS	RSPO1	<10 EU/mg	≥95%^☆, Active
11648-H08H	JAG1	<10 EU/mg	≥95%^☆, Active
10452-HNAH	OSM	<10 EU/mg	≥95%^☆, Active
GMP-10452-HNAH	OSM	<5 EU/mg	≥95%^☆, Active
10573-HNAE	FGF10	<5 EU/mg	≥95%^☆, Active
GMP-10573-HNAE	FGF10	<5 EU/mg	≥95%^☆, Active

☆：SDS-PAGE & SEC-HPLC

【参考文献】

1. Taelman, J., Diaz, M., & Guiu, J. Human Intestinal Organoids: Promise and Challenge. Frontiers in cell and developmental biology, 2022. https://doi.org/10.3389/fcell.2022.854740

2. Kakni, P., et al. PSC-derived intestinal organoids with apical-out orientation as a tool to study nutrient uptake, drug absorption and metabolism. Frontiers in molecular biosciences, 2023. https://doi.org/10.3389/fmolb.2023.1102209

3. Rubert, J., et al. Intestinal Organoids: A Tool for Modelling Diet-Microbiome-Host Interactions. Trends in endocrinology and metabolism: TEM, 2022. https://doi.org/10.1016/j.tem.2020.02.004

4. Günther, C., et al. Organoids in gastrointestinal diseases: from experimental models to clinical translation. Gut, 2022. https://doi.org/10.1136/gutjnl-2021-326560

5. Wang, Q., et al. Applications of human organoids in the personalized treatment for digestive diseases. Signal transduction and targeted therapy, 2022. https://doi.org/10.1038/s41392-022-01194-6

6. Abud, H. E., et al. Source and Impact of the EGF Family of Ligands on Intestinal Stem Cells. Frontiers in cell and developmental biology, 2021. https://doi.org/10.3389/fcell.2021.685665

7. Krause, C., Guzman, A., & Knaus, P. Noggin. The international journal of biochemistry & cell biology, 2011.

https://doi.org/10.1016/j.biocel.2011.01.007

8. Li, Y., et al. Bach2 Deficiency Promotes Intestinal Epithelial Regeneration by Accelerating DNA Repair in Intestinal Stem Cells. Stem cell reports, 2021. https://doi.org/10.1016/j.stemcr.2020.12.005

9. Chen, L., et al. Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients. Frontiers in oncology, 2022. https://doi.org/10.3389/fonc.2022.855674

10. Tang, M., et al. Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma. Biomolecules, 2022. https://doi.org/10.3390/biom12121744

11. Ruan, D., et al. Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. Cell reports. Medicine, 2022. https://doi.org/10.1016/j.xcrm.2022.100849

附件：

研究消化系统疾病模型新工具-肠类器官.docx(未验证)